Anthony R. Braun

This study identifies posaconazole as a more effective and safer alternative to ketoconazole for inhibiting TDP-43 pathology in ALS/FTD by reducing aggregation and restoring SREBP2 levels.

The paper develops FRET biosensors to monitor TDP-43 N-terminal domain interactions and identifies ketoconazole as a potential drug candidate for ALS and FTD.

The paper identifies potent small molecules that inhibit toxic alpha-synuclein oligomers and reduce cell death in SH-SY5Y cells using a FRET-based biosensor platform.

The paper develops a FRET-based biosensor platform to screen small molecules targeting toxic tau oligomers, identifying MK-886 as a compound that disrupts tau oligomers and reduces cytotoxicity.